Current Oncology Reports

, Volume 8, Issue 3, pp 228–236 | Cite as

The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer

  • Debra L. Bemis
  • Jillian L. Capodice
  • Jennifer E. Costello
  • George C. Vorys
  • Aaron E. Katz
  • Ralph Buttyan
Article

Abstract

Having a high probability of experiencing prostate cancer during their lifetime, men are increasingly seeking protection against this disease with the use of over-the-counter dietary supplements containing herbs, vitamins, or plantderived biochemical agents. The use of these agents for prostate cancer prevention is driven by epidemiology supporting the idea that regional diets and consumption of specific dietary components (certain herbs, vitamins, isoflavones, and polyphenols) are associated with a lower risk for prostate cancer, in conjunction with basic research that is defining molecules within food substances that kill or suppress growth of cultured human prostate cancer cells. Moreover, there is a sense that these dietary agents lack side effects, although this assumption often is faulty. Unfortunately, at this time, there is insufficient clinical evidence to support the widespread use of these dietary supplements for chemoprevention of prostate cancer, although ongoing clinical trials of the most promising vitamins and minerals are approaching conclusion.

Keywords

Prostate Cancer Curcumin Resveratrol Prostate Cancer Cell Genistein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    American Cancer Society: Cancer facts and figures, 2005. http://www.cancer.org.Google Scholar
  2. 2.
    Hsieh K, Albertsen PC: Populations at high risk for prostate cancer. Urol Clin North Am 2003, 30:669–676. Good discussion of general risk factors for prostate cancer.PubMedCrossRefGoogle Scholar
  3. 3.
    Flanders WD: Review: prostate cancer epidemiology. Prostate 1984, 5:621–629.PubMedCrossRefGoogle Scholar
  4. 4.
    Crawford ED: Epidemiology of prostate cancer. Urology 2003, 167:3–12. Another nice review of prostate cancer epidemiology.CrossRefGoogle Scholar
  5. 5.
    Yip I, Heber D, Aronson W: Nutrition and prostate cancer. Urol Clin North Am 1999, 26:403–411.PubMedCrossRefGoogle Scholar
  6. 6.
    Clinton SK, Giovannucci E: Diet, nutrition and prostate cancer. Annu Rev Nutr 1998, 18:413–440.PubMedCrossRefGoogle Scholar
  7. 7.
    Sim HG, Cheng CW: Changing demography of prostate cancer in Asia. Eur J Cancer 2005:834–845. Discusses the increasing trend of prostate cancer occurrence in Asian countries.Google Scholar
  8. 8.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. New Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar
  9. 9.
    Dvorkin L, Song KY: Herbs for benign prostatic hyperplasia. Ann Pharmacother 2002, 36:1443–1452.PubMedCrossRefGoogle Scholar
  10. 10.
    Konrad L, Muller HH, Lenz C, et al.: Antiproliferative effect on human prostate cancer cells by stinging nettle root (Urtica dioica) extract. Planta Medica 2000, 66:44–47.PubMedCrossRefGoogle Scholar
  11. 11.
    Goldmann WH, Sharma AL, Currier SJ, et al.: Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 2001, 25:1117–1124.PubMedCrossRefGoogle Scholar
  12. 12.
    Hill B, Kyprianou N: Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate 2004, 61:73–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Davis-Searles PR, Nakanishi Y, Kim NC, et al.: Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005, 65:4484–4457.CrossRefGoogle Scholar
  14. 14.
    Singh RP, Agarwal R: A cancer chemopreventative agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res 2004, 555:21–32.PubMedGoogle Scholar
  15. 15.
    Singh RP, Sharma G, Dhanalakshmi S, et al.: Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003, 12:933–939.PubMedGoogle Scholar
  16. 16.
    Tyagi A, Agarwal C, Agarwal R: The cancer preventative flavonoid silibinin causes hypophosphorylation of Rb/ p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle 2002, 1:137–142.PubMedGoogle Scholar
  17. 17.
    Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R:Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002, 21:1759–1767.PubMedCrossRefGoogle Scholar
  18. 18.
    Jarred RA, Keikha M, Dowling C, et al.: Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002, 11:1689–1696.PubMedGoogle Scholar
  19. 19.
    Clinton S: Lycopene: chemistr y, biolog y and implications for human health and disease. Nutr Rev 1998, 56:35–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Stahl W, Schwarz W, Sundquist AR, Sies H: Cis-trans isomers of lycopene and beta carotene in human serum and tissues. Arch Biochem Biophys 1992, 294:173–177.PubMedCrossRefGoogle Scholar
  21. 21.
    Giovannucci E, Ascherio A, Rimm EB, et al.: Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995, 87:1767–1776.PubMedCrossRefGoogle Scholar
  22. 22.
    Giovannucci E: Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005, 135:2030–2031. Excellent recent review of evidence supporting a role for lycopene as a prostate cancer preventative.Google Scholar
  23. 23.
    Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al.: Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001, 93:1872–1879.PubMedCrossRefGoogle Scholar
  24. 24.
    Tang L, Jin T, Zeng X, Wang JS: Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 2005, 135:287–290.PubMedGoogle Scholar
  25. 25.
    Hantz HL, Young LF, Martin KR: Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med 2005, 230:171–179.Google Scholar
  26. 26.
    Herzog A, Siler U, Spitzer V, et al.: Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005, 19:272–274.PubMedGoogle Scholar
  27. 27.
    Gann PH, Ma J, Giovannucci E, et al.: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999, 59:1225–1230.PubMedGoogle Scholar
  28. 28.
    Nomura AM, Stemmermann GN, Lee J, Craft NE: Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997, 6:487–491.PubMedGoogle Scholar
  29. 29.
    Greenwald P: Clinical trials in cancer prevention: Current results and perspectives for the future. J Nutr 2004, 134:3507–3512. General discussion of ongoing prevention trials involving food derived substances.Google Scholar
  30. 30.
    Schneider C: Chemistry and biology of vitamin E. Mol Nutr Food Res 2005, 49:7–30. Good review of vitamin E and its effects.PubMedCrossRefGoogle Scholar
  31. 31.
    Traber MG, Arai H: Molecular mechanisms of vitamin E transport. Annu Rev Nutr 1999, 19:343–355.PubMedCrossRefGoogle Scholar
  32. 32.
    Heinonen OP, Albanes D, Virtamo J, et al.: Prostate cancer and supplementation with alpha-tocopherol and betacarotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440–446.PubMedCrossRefGoogle Scholar
  33. 33.
    Traber MG, Packer L: Vitamin E: beyond antioxidant function. Am J Clin Nutr 1995, 62:1501S-1509S.PubMedGoogle Scholar
  34. 34.
    Nelson WG, DeWeese TL, DeMarzo AM: The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002, 21:3–16. Excellent discussion of the potential role of inflammation in prostate cancer.PubMedCrossRefGoogle Scholar
  35. 35.
    Gunawardena K, Murray DK, Meikle AW: Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 2000, 44:287–295.PubMedCrossRefGoogle Scholar
  36. 36.
    Venkateswaran V, Fleshner NE, Klotz LH: Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002, 168:1578–1582.PubMedCrossRefGoogle Scholar
  37. 37.
    Fleshner N, Fair WR, Huryk R, Heston WD: Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999, 161:1651–1654.PubMedCrossRefGoogle Scholar
  38. 38.
    Grant WB, Holick MF: Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005, 10:94–111.PubMedGoogle Scholar
  39. 39.
    Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990, 10:1307–1311.PubMedGoogle Scholar
  40. 40.
    Giovannucci E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998, 9:567–582.PubMedCrossRefGoogle Scholar
  41. 41.
    Chen TC, Holick MF: Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003, 14:423–430.PubMedCrossRefGoogle Scholar
  42. 42.
    Krishnan AV, Peehl DM, Feldman D: Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003, 88:363–371.PubMedCrossRefGoogle Scholar
  43. 43.
    Peehl DM, Krishnan AV, Feldman D: Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003, 133(suppl 7):2461S-2469S.PubMedGoogle Scholar
  44. 44.
    Zhao XY, Ly LH, Peehl DM, Feldman D: Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999, 140:1205–1212.PubMedCrossRefGoogle Scholar
  45. 45.
    Kim YS, Milner J: Molecular targets for selenium in cancer prevention. Nutr Cancer 2001, 40:50–54.PubMedCrossRefGoogle Scholar
  46. 46.
    Clark LC, Combs GF, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276:1957–1963.PubMedCrossRefGoogle Scholar
  47. 47.
    Brooks JD, Metter EJ, Chan DW, et al.: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001, 166:2034–2038.PubMedCrossRefGoogle Scholar
  48. 48.
    Vogt TM, Ziegler RG, Graubard BI, et al.: Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 2003, 103:664–670.PubMedCrossRefGoogle Scholar
  49. 49.
    Allen NE, Morris JS, Ngwenyama RA, Key TJ: A case-control study of selenium in nails and prostate cancer risk in British men. Br J Cancer 2004, 90:1392–1396.PubMedCrossRefGoogle Scholar
  50. 50.
    Yamaguchi K, Uzzo RG, Pimkina J, et al.: Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005, 24:5868–5877.PubMedCrossRefGoogle Scholar
  51. 51.
    Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003, 63:52–59.PubMedGoogle Scholar
  52. 52.
    Corcoran NM, Najdovska M, Costello AJ: Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004, 171:907–910.PubMedCrossRefGoogle Scholar
  53. 53.
    Lee MM, Gomez SL, Chang JS, et al.: Soy and isof lavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003, 12:665–668.PubMedGoogle Scholar
  54. 54.
    Holzbeierlein JM, McIntosh J, Thrasher JB: The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 2005, 15:17–22. Nice review of soy isoflavones and their role in prostate cancer chemoprevention.PubMedCrossRefGoogle Scholar
  55. 55.
    Sarkar FH, Li Y: Soy isoflavones and cancer progression. Cancer Invest 2003, 21:744–757.PubMedCrossRefGoogle Scholar
  56. 56.
    Akiyama T, Ishida J, Nakagawa S, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262:5592–5595.PubMedGoogle Scholar
  57. 57.
    Constantinou A, Mehta R, Runyan C, et al.: Flavonoids as DNA topoisomerase antagonists and poisons: structureactivity relationships. J Nat Prod 1995, 58:217–225.PubMedCrossRefGoogle Scholar
  58. 58.
    Fotsis T, Pepper M, Adlercreutz H, et al.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A 1993, 90:2690–2694.PubMedCrossRefGoogle Scholar
  59. 59.
    Shen JC, Klein RD, Wei Q, et al.: Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000, 29:92–102.PubMedCrossRefGoogle Scholar
  60. 60.
    Mentor-Marcel R, Lamartiniere CA, Eltoum IA, et al.: Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 2005, 135:989–995.PubMedGoogle Scholar
  61. 61.
    Hikosaka A, Asamoto M, Hokaiwado N, et al.:Inhibitor y effects of soy isof lavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[ 4,5-b]pyridine (PhIP). Carcinogenesis 2004, 25:381–387.PubMedCrossRefGoogle Scholar
  62. 62.
    Bemis DL, Capodice JL, Desai M, et al.: A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 2004, 10:5282–5292.PubMedCrossRefGoogle Scholar
  63. 63.
    Kumar NB, Cantor A, Allen K, et al.: The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004, 59:141–147. Another excellent summar y of soy isof lavones and prostate cancer risk.PubMedCrossRefGoogle Scholar
  64. 64.
    Dalais FS, Meliala A, Wattanapenpaiboon N, et al.: Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004, 64:510–515.PubMedCrossRefGoogle Scholar
  65. 65.
    Spentzos D, Mantzoros C, Regan MM, et al.: Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res 2003, 9:3282–3287.PubMedGoogle Scholar
  66. 66.
    Gupta S, Ahmad N, Mukhtar H: Prostate cancer chemoprevention by green tea. Semin Urol Oncol 1999, 17:70–76. Review of green tea-derived polyphenols and potential use as prostate cancer preventative.PubMedGoogle Scholar
  67. 67.
    Saleem M, Adhami VM, Siddiqui IA, Mukhtar H: Tea beverage in chemoprevention of prostate cancer: a mini-review. Nutr Cancer 2003, 47:13–23.PubMedCrossRefGoogle Scholar
  68. 68.
    Ren F, Zhang S, Mitchell SH, et al.: Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000, 19:1924–1932.PubMedCrossRefGoogle Scholar
  69. 69.
    Hastak K, Gupta S, Ahmad N, et al.: Role of p53 and NFkappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003, 22:4851–4859.PubMedCrossRefGoogle Scholar
  70. 70.
    Hastak K, Agarwal MK, Mukhtar H, Agarwal ML: Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005, 19:789–791.PubMedGoogle Scholar
  71. 71.
    Gupta S, Hastak K, Ahmad N, et al.: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001, 98:10350–10355.PubMedCrossRefGoogle Scholar
  72. 72.
    Roomi MW, Ivanov V, Kalinovsky T, et al.: In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo 2005, 19:179–183.PubMedGoogle Scholar
  73. 73.
    Adhami VM, Siddiqui IA, Ahmad N, et al.: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004, 64:8715–8722.PubMedCrossRefGoogle Scholar
  74. 74.
    Choan E, Segal R, Jonker D, et al.: A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005, 23:108–113.PubMedGoogle Scholar
  75. 75.
    Jatoi A, Ellison N, Burch PA, et al.: A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97:1442–1446.PubMedCrossRefGoogle Scholar
  76. 76.
    Ratan HL, Steward WP, Gescher AJ, Mellon JK: Resveratrol-a prostate cancer chemopreventive agent? Urol Oncol 2002, 7:223–227. General review on resveratrol and its potential as prostate cancer preventative.PubMedCrossRefGoogle Scholar
  77. 77.
    Hsieh TC, Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999, 249:109–115.PubMedCrossRefGoogle Scholar
  78. 78.
    Kim YA, Rhee SH, Park KY, Choi YH: Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003, 6:273–280.PubMedCrossRefGoogle Scholar
  79. 79.
    Narayanan BA, Narayanan NK, Re GG, Nixon DW: Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 2003, 104:204–212.PubMedCrossRefGoogle Scholar
  80. 80.
    Lin HY, Shih A, Davis FB, et al.: Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 2002, 168:748–755.PubMedCrossRefGoogle Scholar
  81. 81.
    Mitchell SH, Zhu W, Young CY: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999, 59:5892–5895.PubMedGoogle Scholar
  82. 82.
    Joe B, Vijaykumar M, Lokesh BR: Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004, 44:97–111. Nice, general review on curcumin and its effects on prostate cancer cells.PubMedCrossRefGoogle Scholar
  83. 83.
    Sharma OP: Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976, 25:1811–1822.PubMedCrossRefGoogle Scholar
  84. 84.
    Satoskar RR, Shah SJ, Shenoy SG: Evaluation of antiin flammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 1986, 24:651–654.PubMedGoogle Scholar
  85. 85.
    Dorai T, Gehani N, Katz A: Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000, 4:1–6.PubMedGoogle Scholar
  86. 86.
    Ohtsu H, Xiao Z, Ishida J, et al.: Curcumin analogues as novel androgen receptor antagonists with potential as antiprostate cancer agents. J Med Chem 2002, 45:5037–5042.PubMedCrossRefGoogle Scholar
  87. 87.
    Chaudhary LR, Hruska KA: Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003, 89:1–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Deeb D, Jiang H, Gao X, et al.: Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 2004, 3:803–812.PubMedGoogle Scholar
  89. 89.
    Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer-V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004, 60:1–17.PubMedCrossRefGoogle Scholar
  90. 90.
    Dorai T, Cao YC, Dorai B, et al.: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001, 47:293–303.PubMedCrossRefGoogle Scholar
  91. 91.
    Imaida K, Tamano S, Kato K, et al.: Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 2001, 22:467–472.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  • Debra L. Bemis
  • Jillian L. Capodice
  • Jennifer E. Costello
  • George C. Vorys
  • Aaron E. Katz
  • Ralph Buttyan
    • 1
  1. 1.Department of UrologyColumbia UniversityNew YorkUSA

Personalised recommendations